For instance, since the concept that KRAS mutant colorectal cancer patients do not benefit from the addition of EGFR antibodies to the chemotherapy backbone was introduced, determination of RAS status has become part of the routine diagnostic workup in patients with advanced colorectal cancer (Di Fiore et al. 2007; Karapetis et al. 2008). This evidence concerns the gene KRAS and colorectal cancer.